1367. Assessment of the Quality-of-Life for patients and caregivers with High Grade Gliomas

Authors: Luke Alan Mugge; Mitra Jamshidian; Justin Baum; Yasaman Alam; Jason Schroeder (Perrysburg, OH)

Introduction: Treatment of both benign and malignant primary and metastatic brain lesions is a central aspect of neurosurgical care. As treatment innovations continue to be introduced, patients are enjoying ever longer periods of progression-free survival.

Methods: The charts of patients with pathologically confirmed diagnosis of either a high-grade glioma or an anaplastic astrocytoma were reviewed for features related to the overall quality of life. A standardized questionnaire was created and given to the patient’s caregiver after treatment was complete.

Results: Twenty-seven patients were identified and seventeen ultimately met inclusion criteria. The average age for this cohort was 65 years. The approximate cost for each patient ranged from 110 to 50K with the average in-facility treatment time being 34 days. In terms of the analysis of the quality of life, sixty-five percent of caregivers indicated they were burdened emotionally by caring for their loved one. Behind this, twenty-three percent of caregivers indicated they felt that they were socially burdened by caring for a patient with this disease. In terms of the caregiver reporting disease burden for the patient, caregivers reported that the physical burdens of the disease were the most significant in 59% of cases, 29% of caregivers reported that emotional burdens were most intrusive, and 12% indicated that social burdens were most intrusive for the patient.

Conclusion: It is clear that as treatment of high grade gliomas improves that the quality of life must continue to be used as a metric in terms of measuring efficacy. While doing this, it is also clear the burdens experienced by the patient are not shared by the caregiver. Finally, it should be recognized that, at a given point of disease progression, additional interventions only stand to hinder the quality of life without significantly improving the prognosis.